Metamizol Kalceks

Metamizole, the active ingredient in Metamizol Kalceks, is a pyrazolone presented as an injectable solution for intramuscular and intravenous use. It is employed to relieve moderate to severe pain and to reduce fever in adult patients, offering rapid onset of action in acute clinical settings.

GNH USA supplies Metamizol Kalceks as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide, adhering to stringent quality standards and regulatory requirements. The company ensures compliance with EU Good Manufacturing Practice and provides reliable cold‑chain logistics for temperature‑sensitive products.

Metamizole is an analgesic/antipyretic that acts on pain and fever pathways.

- Pain: provides rapid relief of moderate to severe pain. - Fever: lowers elevated body temperature. - Postoperative pain: controls pain following surgical procedures. - Cancer‑related pain: helps manage pain associated with malignancies. - Acute musculoskeletal pain: alleviates pain from injuries or strains.

Metamizole may be associated with a range of adverse reactions, varying from mild to severe.

Common Side Effects: - Injection site pain: discomfort at the site of intramuscular or intravenous administration. - Transient hypotension: brief drop in blood pressure after injection. - Nausea: feeling of sickness often accompanied by stomach upset. - Vomiting: expulsion of stomach contents. - Dizziness: light‑headed sensation. - Mild skin rash: limited erythema or itching.

Serious or Rare Side Effects: - Agranulocytosis: severe reduction of white blood cells that can lead to infection. - Anaphylactic reaction: life‑threatening allergic response with airway compromise. - Stevens‑Johnson syndrome: severe skin and mucous membrane disorder. - Severe neutropenia: markedly low neutrophil count increasing infection risk. - Blood dyscrasias: abnormal blood cell formation. - Hypotensive shock: profound circulatory collapse.

When using Metamizole, several precautions should be observed to minimize risk.

- Renal function assessment: evaluate kidney status before initiating therapy. - Hematologic monitoring: perform regular complete blood counts to detect early blood dyscrasias. - Hypersensitivity avoidance: do not administer to patients with known allergy to pyrazolones. - Cardiovascular caution: use carefully in patients with unstable blood pressure or heart disease. - Concomitant myelosuppressants: avoid combining with other agents that suppress bone marrow. - Store at 2-8°C: keep refrigerated, protect from light, do not freeze or shake.

Metamizole can interact with other medicines, altering efficacy or safety.

Major Interactions (Avoid): - Myelosuppressive agents: concurrent use may increase risk of agranulocytosis. - ACE inhibitors: combined therapy can enhance hypotensive effects. - Other NSAIDs or pyrazolones: additive risk of renal and gastrointestinal toxicity.

Moderate Interactions (Monitor Closely): - Anticoagulants: may increase bleeding tendency. - Diuretics: potential for altered renal clearance. - Lithium: Metamizole may affect lithium plasma levels.